Lexicon Pharmaceuticals announced it will present clinical study data on sotagliflozin for Type 1 diabetes and pilavapadin for diabetic peripheral neuropathic pain at the American Diabetes Association 2026 Scientific Sessions in New Orleans. The company highlighted consistent A1c reductions with sotagliflozin across patient subgroups and pharmacokinetic data for pilavapadin. An NDA resubmission for sotagliflozin in T1D is on track for mid-year 2026.

Hypertrophic cardiomyopathy (HCM) is a complex genetic heart condition causing thickening and stiffening of the heart muscle, leading to symptoms like fatigue, breathlessness, and chest discomfort. The condition can develop at any age and carries risks of serious complications including heart failure and sudden death. While no medications currently prevent HCM, treatments for obstructive HCM may include cardiac myosin inhibitors. Lexicon Pharmaceuticals is conducting the SONATA-HCM clinical trial to investigate sotagliflozin, a potential new treatment that may improve symptoms and reduce heart failure events.

Lexicon Pharmaceuticals announced results from its PROGRESS Phase 2b study of pilavapadin in diabetic peripheral neuropathic pain (DPNP), supporting the selection of 10mg as the optimal dose for Phase 3 development. The drug achieved nominally significant reduction in average pain at Week 8 versus placebo with good tolerability. Additional preclinical data on spasticity in multiple sclerosis and spinal cord injury models will also be presented at the American Academy of Neurology Annual Meeting.

Lexicon Pharmaceuticals closed a $94.6 million public offering of 32 million common shares at $1.30 per share and a concurrent private placement of 22.4 million common shares and 367,145 Series B convertible preferred shares at $65 per share on February 2, 2026. The company plans to use net proceeds for research and development of drug candidates and general corporate purposes.

Lexicon Pharmaceuticals closed a $94.6 million public offering of 32 million common shares at $1.30 per share and a concurrent private placement of 22.4 million common shares and 367,145 Series B convertible preferred shares at $65 per share on February 2, 2026. The company intends to use the net proceeds to fund research and development of drug candidates and for general corporate purposes. Underwriters were granted a 30-day option to purchase up to 4.8 million additional shares.

Lexicon Pharmaceuticals announced the pricing of a $94.6 million capital raise consisting of a $41.6 million public offering of 32 million common shares at $1.30 per share and a $52.9 million concurrent private placement to Invus affiliate. The offering is expected to close February 2, 2026, with proceeds designated for R&D of drug candidates and general corporate purposes.

A clinical study demonstrated sotagliflozin's potential benefits for heart failure patients with preserved ejection fraction (HFpEF) without diabetes, showing significant improvements in cardiac structure, function, and quality of life.

Lexicon Pharmaceuticals submitted additional clinical data to the FDA for Zynquista®, an oral SGLT1/SGLT2 inhibitor for type 1 diabetes, following a complete response letter in December 2024. The FDA requires more time to review the data and will provide feedback in Q4 2025.

Lexicon Pharmaceuticals will present patient survey data on diabetic peripheral neuropathic pain (DPNP) at the American Society of Pain and Neuroscience meeting, highlighting their investigational non-opioid treatment pilavapadin.

U.S. stock futures fell on Monday after three consecutive days of decline. Goldman Sachs has increased its U.S. recession probability from 20% to 35% and warned that the risk of further market correction is still looming.

Three small-cap stocks, Argan, Lightwave Logic, and Lexicon Pharmaceuticals, posted significant gains last week despite broader market uncertainty, with Lexicon surging 58% on a licensing deal with Novo Nordisk.

Lexicon Pharmaceuticals reported progress on its pipeline, including positive topline results for its DPNP drug candidate pilavapadin and continued enrollment in a Phase 3 trial for its SGLT1/2 inhibitor sotagliflozin in hypertrophic cardiomyopathy. The company also provided financial results for Q4 2024 and full-year 2024.